Bausch Health Companies Inc. Repayments of Convertible Debt
Bausch Health Companies Inc. (BHC) reported Repayments of Convertible Debt of $0 for the 9-month period ending 2016-09-30, per its 10-Q filed 2016-11-09.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfConvertibleDebt · last filed 2016-11-09
- Bausch Health Companies Inc. repayments of convertible debt for the quarter ending 2016-09-30 was $0.00.
- Bausch Health Companies Inc. repayments of convertible debt for the quarter ending 2015-09-30 was $0.00.
- Bausch Health Companies Inc. repayments of convertible debt for the quarter ending 2013-12-31 was $0.00.
- Bausch Health Companies Inc. repayments of convertible debt for the quarter ending 2013-09-30 was $0.00.
- Bausch Health Companies Inc. repayments of convertible debt for fiscal 2013 was $0.00, a 100.00% decline from fiscal 2012.
- Bausch Health Companies Inc. repayments of convertible debt for fiscal 2012 was $3.98M, a 99.35% decline from fiscal 2011.
- Bausch Health Companies Inc. repayments of convertible debt for fiscal 2011 was $613.47M, a 141.22% increase from fiscal 2010.
- Bausch Health Companies Inc. repayments of convertible debt for fiscal 2010 was $254.32M.
| Period end | Repayments of Convertible Debt 3 month | Repayments of Convertible Debt 6 month | Repayments of Convertible Debt 9 month | Repayments of Convertible Debt 12 month |
|---|---|---|---|---|
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $0.00 10-Q · filed 2016-11-09 | ||
| 2016-06-30 | $0.00 10-Q · filed 2016-08-09 | |||
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $3.12B 10-Q · filed 2016-11-09 | ||
| 2015-06-30 | $3.12B 10-Q · filed 2016-08-09 | |||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | $0.00 derived: sum of 2 quarters · filed 2014-02-28 | $0.00 derived: sum of 3 quarters · filed 2014-02-28 | $0.00 10-K · filed 2014-02-28 |
| 2013-09-30 | $0.00 10-Q · filed 2013-11-01 | $0.00 derived: sum of 2 quarters · filed 2013-11-01 | $0.00 10-Q · filed 2013-11-01 | $0.00 derived: sum of 4 quarters · filed 2014-02-28 |
| 2013-06-30 | $0.00 10-Q · filed 2013-08-07 | $0.00 10-Q · filed 2013-08-07 | $0.00 derived: sum of 3 quarters · filed 2014-02-28 | $0.00 derived: sum of 4 quarters · filed 2014-02-28 |
| 2013-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2014-02-28 | $0.00 derived: sum of 2 quarters · filed 2014-02-28 | $0.00 derived: sum of 3 quarters · filed 2014-02-28 | $0.00 derived: sum of 4 quarters · filed 2014-02-28 |
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | $0.00 derived: sum of 2 quarters · filed 2014-02-28 | $0.00 derived: sum of 3 quarters · filed 2014-02-28 | $3.98M 10-K · filed 2014-02-28 |
| 2012-09-30 | $0.00 10-Q · filed 2013-11-01 | $0.00 derived: sum of 2 quarters · filed 2013-11-01 | $3.98M 10-Q · filed 2013-11-01 | $75.85M derived: sum of 4 quarters · filed 2014-02-28 |
| 2012-06-30 | $0.00 10-Q · filed 2013-08-07 | $3.98M 10-Q · filed 2013-08-07 | $75.85M derived: sum of 3 quarters · filed 2014-02-28 | $278.43M derived: sum of 4 quarters · filed 2014-02-28 |
| 2012-03-31 | $3.98M 10-Q · filed 2013-05-03 | $75.85M derived: sum of 2 quarters · filed 2014-02-28 | $278.43M derived: sum of 3 quarters · filed 2014-02-28 | $478.22M derived: sum of 4 quarters · filed 2014-02-28 |
| 2011-12-31 | $71.87M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | $274.46M derived: sum of 2 quarters · filed 2014-02-28 | $474.25M derived: sum of 3 quarters · filed 2014-02-28 | $613.47M 10-K · filed 2014-02-28 |
| 2011-09-30 | $202.59M 10-Q · filed 2012-11-05 | $402.38M derived: sum of 2 quarters · filed 2012-11-05 | $541.60M 10-Q · filed 2012-11-05 | |
| 2011-06-30 | $199.79M 10-Q · filed 2012-08-03 | $339.01M 10-Q · filed 2012-08-03 | ||
| 2011-03-31 | $139.22M 10-Q · filed 2012-05-04 | |||
| 2010-12-31 | $254.32M 10-K · filed 2013-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |